Table 1.
Patient Information
| Pt No. | Sex/Age | Pathology | Radiotherapy | Physical Dose (Gy) | T1/2 of ICG clearance (min) | Break during RT |
Previous Treatments | |||
|---|---|---|---|---|---|---|---|---|---|---|
|
|
||||||||||
| During RT | End RT | Prior RT | During RT | 1 month after RT | ||||||
|
| ||||||||||
| 1* | M/59 | HCC | 3D Conformal | 32.5 | 50 | 8.59 | 10.55 | 10.44 | no | TACE / Radioembolization |
| 2 | M/72 | HCC | SBRT | 40 | 50 | 5.00 | 4.00 | 4.50 | no | none |
| 3 | M/54 | cholangiocarcinoma | 3D Conformal | 36 | 62 | 4.50 | 4.25 | 4.75 | no | none |
| 4* | M/60 | HCC | SBRT | NA | 30 | 9.95 | NA | 11.31 | yes | TACE / RFA |
| 5 | M/72 | HCC | IMRT | 32.5 | 50 | 5.07 | 6.24 | 6.19 | yes | none |
| 6* | M/73 | HCC | SBRT | 40 | 50 | 4.68 | 5.82 | 6.56 | yes | TACE |
| 7 | M/71 | cholangiocarcinoma | 3D Conformal | 36 | 64.8 | 5.26 | 4.75 | 5.25 | yes | none |
| 8* | M/67 | HCC | SBRT | NA | 30 | 13.96 | NA | 14.64 | yes | RFA |
| 9 | F/66 | cholangiocarcinoma | IMRT | 36 | 54 | 4.68 | 4.15 | 4.37 | no | none |
| 10* | M/61 | HCC | SBRT | 22 | 33 | 11.83 | NA | 11.27 | yes | TACE / RFA |
| 11 | M/44 | HCC | IMRT | 26 | 52 | 11.31 | 4.07 | 7.27 | yes | none |
| 12 | M/83 | HCC | SBRT | 8.5 | 17 | 5.06 | 5.29 | NA | yes | TACE |
| 13 | M/58 | esophageal metastasis | SBRT | 36 | 60 | 5.19 | 5.62 | 6.86 | yes | RT |
| 14* | M/59 | HCC | SBRT | NA | 33 | 13.67 | NA | 13.09 | yes | TACE |
HCC: hepatocellular carcinoma; ICG: indocyanine green; NA: data not available; TACE: transcatheter arterial chemoembolization; RFA: radiofrequency ablation; RT: radiation therapy.
*
patient with cirrhosis.